What’s New for Biologics | FDA

What’s New for Biologics | FDA

Posted: 08/11/2020

• Vaccines and Related Biological Products Advisory Committee October 2, 2020 Meeting Announcement

8/12/2020	CBER-Regulated Products: Resolved Shortages
8/11/2020	Vaccines and Related Biological Products Advisory Committee October 2, 2020 Meeting Announcement
8/7/2020	BK200449 – Healeon Duet
8/5/2020	Workshop Agenda - Use of Real World Evidence to Support Effectiveness of Preventive Vaccines
8/5/2020	Influenza Vaccine for the 2020-2021 Season
8/4/2020	Complete List of Licensed Products and Establishments
8/4/2020	Complete List of Substantially Equivalent 510(k) Device Applications
8/4/2020	Complete List of Currently Approved Premarket Approvals (PMAs)
8/4/2020	Complete List of Currently Approved NDA and ANDA Application Submissions
8/3/2020	BK200491 - iWeBB electronic Laboratory Information System (iWeBB-eLIS) v1.0.0
8/3/2020	Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations
8/3/2020	MedWatch to Manufacturer Program
7/31/2020	CBER-Regulated Products: Resolved Shortages
7/31/2020	CBER-Regulated Products: Current Shortages
7/28/2020	Influenza neuraminidase antigenicity and efficacy in vaccines
7/28/2020	July 28, 2020 Approval Letter - MENVEO
7/28/2020	Exceptions and Alternative Procedures Approved Under 21 CFR 640.120
7/28/2020	User Fee Billable Biologic Products and Potencies Approved Under Section 351 of PHS Act
7/28/2020	July 22, 2020 Untitled Letter - American Medical Aesthetics and Regenerative Medicine Inc.
7/24/2020	July 24, 2020 Approval Letter - TECARTUS
7/24/2020	CBER-Regulated Products: Current Shortages
7/22/2020	2020 Biological Device Application Approvals
7/22/2020	2020 Biological License Application Approvals
7/22/2020	2020 Biological License Application Supplement Noteworthy Approvals
7/22/2020	Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
7/22/2020	Reporting Adverse Events Related to Stem Cells, Exosomes, or Other Products Marketed as Regenerative Medicine Products
7/20/2020	TRG Rapid Inquiry Program (TRIP)
7/20/2020	Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use; Guidance for Industry and Food and Drug Administration Staff
7/16/2020	Considerations for the Use of Real-World Evidence to Assess the Effectiveness of Preventive Vaccines
7/14/2020	Diagnosis and Pathogenesis of Hepatitis Viruses That Impact the Safety of Blood and Related Products
7/13/2020	Understanding the Interplay Between Host Immunity and Viral Factors for Rational Design of Vaccines Against Vector-Borne Viral Pathogens